New InhA Inhibitors Based on Expanded Triclosan and <i>Di</i>-Triclosan Analogues to Develop a New Treatment for Tuberculosis

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely c...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Sarentha Chetty, Tom Armstrong, Shalu Sharma Kharkwal, William C. Drewe, Cristina I. De Matteis, Dimitrios Evangelopoulos, Sanjib Bhakta, Neil R. Thomas
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	MDPI AG 2021-04-01
סדרה:	Pharmaceuticals
נושאים:	tuberculosis structure-based drug-design molecular modelling InhA triazole triclosan
גישה מקוונת:	https://www.mdpi.com/1424-8247/14/4/361
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!